Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 11/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.43 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487966 | 0.97 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL26112589 | 0.78 | L3MBTL3 (0.52) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL26117153 | 0.78 | L3MBTL3 (0.52) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL1813299 | 0.78 | — | — | |
| SCHEMBL1645817 | 0.78 | PHGDH (0.48) | L3MBTL3L3MBTL1KDM4EHTR6 | |
| SCHEMBL17782707 | 0.78 | PHGDH (0.43) | L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL1371575 | 0.77 | SMN1; SMN2 (0.44) | L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL24511688 | 0.77 | L3MBTL3 (0.52) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL274111 | 0.77 | PHGDH (0.37) | L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL18946139 | 0.77 | L3MBTL3 (0.52) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | claimed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | claimed |
| CN-105829285-A | Quinazolinone and isoquinolinone derivatives | 中外制药株式会社 | 2016-08-03 | — | — | CN | disclosed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | L3MBTL3 3627/4885L3MBTL1 2924/4885MBTD1 3410/4885 |
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | L3MBTL3 914/4885L3MBTL1 864/4885MBTD1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.